Myriad Genetics (MYGN)
(Delayed Data from NSDQ)
$27.39 USD
+0.75 (2.82%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $27.38 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Brokerage Reports
Myriad Genetics, Inc. [MYGN]
Reports for Purchase
Showing records 201 - 220 ( 244 total )
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
MYGN: 2013 Reimbursement Uncertainty for BRACAnalysis Takes Us to the Sidelines Downgrading to NEUTRAL
Provider: COLLIERS SECURITIES
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
MYGN: BRACAnalysis Reimbursement is on the Lab Schedule, Which is a Positive But No Clarity on the 2013 Rates Until September 28th
Provider: COLLIERS SECURITIES
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Medical Technology: Thoughts on Our Medical Technology Universe Heading Into the Dog Days of Summer
Provider: COLLIERS SECURITIES
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
MYGN: Solid Numbers in F3Q:12
Provider: COLLIERS SECURITIES
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
MYGN: Supreme Court in Conference Today, Decision on Whether They Hear ACLU Case Expected Monday 10 AM Thoughts From Our IP Expert
Provider: COLLIERS SECURITIES
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
MYGN: Mayo v. Prometheus Decision Overblown Reiterate MYGN Buy
Provider: COLLIERS SECURITIES
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
MYGN: Steady BRACAnalysis Business, Intl. Opportunities Pending, New Products Over the Horizon Initiating with a BUY Rating
Provider: COLLIERS SECURITIES
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
F2Q12 Results: Nice Beat and Raise as Colaris Continues to Surprise; Raising Estimates, PT to $28
Provider: AURIGA USA
Analyst: MCDONALD P
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
F1Q12 Results Review: Strong Performance Across the Board as Colaris Shines
Provider: AURIGA USA
Analyst: MCDONALD P
Company: Myriad Genetics, Inc.
Industry: Medical - Biomedical and Genetics
Patience Will Be Rewarded; Upgrading to Buy, Raising PT to $24
Provider: AURIGA USA
Analyst: MCDONALD P